{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:10:49Z","timestamp":1780733449342,"version":"3.54.1"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,5,2]],"date-time":"2021-05-02T00:00:00Z","timestamp":1619913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,2]],"date-time":"2021-05-02T00:00:00Z","timestamp":1619913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pfizer Spain"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To establish practical recommendations for the management of patients with psoriatic arthritis (PsA) with particular clinical situations that might lead to doubts in the pharmacological decision-making. A group of six expert rheumatologists on PsA identified particular clinical situations in PsA. Then, a systematic literature review (SLR) was performed to analyse the efficacy and safety of csDMARDs, b\/tsDMARDs in PsA. In a nominal group meeting, the results of the SLR were discussed and a set of recommendations were proposed for a Delphi process. A total of 65 rheumatologists were invited to participate in the Delphi. Agreement was defined if\u2009\u2265\u200970% of the participants voted\u2009\u2265\u20097 (from 1, totally disagree to 10, totally agree). For each recommendation, the level of evidence and grade of recommendation was established based on the Oxford Evidence-Based Medicine categorisation. Particular clinical situations included monoarthritis, axial disease, or non-musculoskeletal manifestations. The SLR finally comprised 131 articles. A total of 16 recommendations were generated, all but 1 reached consensus. According to them, it is crucial to carefully analyse the impact of individual manifestations on patients (disability, quality of life, etc.), but also to recognise the impact of each drug singularities on selected clinical phenotypes  to adopt the most appropriate treatment strategy. Early diagnosis and treatment to target approach, along with a close risk management, is also necessary. These recommendations are intended to complement gaps in national and international guidelines by helping health professionals address and manage particular clinical situations in PsA.<\/jats:p>","DOI":"10.1007\/s00296-021-04877-5","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T15:39:10Z","timestamp":1620056350000},"page":"1549-1565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Management of particular clinical situations in psoriatic arthritis: an expert\u2019s recommendation document based on systematic literature review and extended Delphi process"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9096-3780","authenticated-orcid":false,"given":"Rosario","family":"Garc\u00eda-Vicu\u00f1a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5337-2970","authenticated-orcid":false,"given":"Susana","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1140-7618","authenticated-orcid":false,"given":"Beatriz","family":"Joven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-7145","authenticated-orcid":false,"given":"Rub\u00e9n","family":"Queiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7047-8056","authenticated-orcid":false,"given":"Julio","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3651-3687","authenticated-orcid":false,"given":"Francisco","family":"Rebollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4607-9178","authenticated-orcid":false,"given":"Est\u00edbaliz","family":"Loza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2812-2467","authenticated-orcid":false,"given":"Agust\u00ed","family":"Sellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,2]]},"reference":[{"issue":"3","key":"4877_CR1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.berh.2019.01.002","volume":"32","author":"JW Liew","year":"2018","unstructured":"Liew JW, Ramiro S, Gensler LS (2018) Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis. Best Pract Res Clin Rheumatol 32(3):369\u2013389. https:\/\/doi.org\/10.1016\/j.berh.2019.01.002","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"9","key":"4877_CR2","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1093\/rheumatology\/keaa062","volume":"59","author":"B Pittam","year":"2020","unstructured":"Pittam B, Gupta S, Harrison NL, Robertson S, Hughes DM, Zhao SS (2020) Prevalence of extra-articular manifestations in psoriatic arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 59(9):2199\u20132206. https:\/\/doi.org\/10.1093\/rheumatology\/keaa062","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"4877_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00296-020-04775-2","volume":"41","author":"S Gupta","year":"2021","unstructured":"Gupta S, Syrimi Z, Hughes DM, Zhao SS (2021) Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol Int 41(2):275\u2013284. https:\/\/doi.org\/10.1007\/s00296-020-04775-2","journal-title":"Rheumatol Int"},{"issue":"6","key":"4877_CR4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, Primdahl J, McGonagle DG, Aletaha D, Balanescu A, Balint PV, Bertheussen H, Boehncke WH, Burmester GR, Canete JD, Damjanov NS, Kragstrup TW, Kvien TK, Landewe RBM, Lories RJU, Marzo-Ortega H, Poddubnyy D, Rodrigues Manica SA, Schett G, Veale DJ, Van den Bosch FE, van der Heijde D, Smolen JS (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(6):700\u2013712. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217159","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4877_CR5","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1136\/annrheumdis-2020-217163","volume":"79","author":"A Kerschbaumer","year":"2020","unstructured":"Kerschbaumer A, Smolen JS, Dougados M, de Wit M, Primdahl J, McInnes I, van der Heijde D, Baraliakos X, Falzon L, Gossec L (2020) Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 79(6):778\u2013786. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217163","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4877_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","volume":"77","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Schols M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewe R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 77(1):3\u201317. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211734","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4877_CR7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13075-018-1659-z","volume":"20","author":"G Haugeberg","year":"2018","unstructured":"Haugeberg G, Michelsen B, Tengesdal S, Hansen IJW, Diamantopoulos A, Kavanaugh A (2018) Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. Arthritis Res Ther 20(1):160. https:\/\/doi.org\/10.1186\/s13075-018-1659-z","journal-title":"Arthritis Res Ther"},{"key":"4877_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.10.031","author":"K Colaco","year":"2020","unstructured":"Colaco K, Widdifield J, Luo J, Rosen CF, Alhusayen R, Paterson JM, Campbell W, Tu K, Bernatsky S, Gladman DD, Eder L (2020) Trends in mortality and cause-specific mortality among patients with psoriasis and psoriatic arthritis in Ontario, Canada. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2020.10.031","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"4877_CR9","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/acr.22860","volume":"68","author":"P Vashisht","year":"2016","unstructured":"Vashisht P, Sayles H, Cannella AC, Mikuls TR, Michaud K (2016) Generalizability of patients with rheumatoid arthritis in biologic agent clinical trials. Arthritis Care Res (Hoboken) 68(10):1478\u20131488. https:\/\/doi.org\/10.1002\/acr.22860","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"4877_CR10","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, Bautista-Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Husni ME, Love TJ, Lubrano E, McHugh N, Nash P, Ogdie A, Orbai AM, Parkinson A, O\u2019Sullivan D, Rosen CF, Schwartzman S, Siegel EL, Toloza S, Tuong W, Ritchlin CT (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68(5):1060\u20131071. https:\/\/doi.org\/10.1002\/art.39573","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"4877_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J (2019) Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol 71(1):5\u201332. https:\/\/doi.org\/10.1002\/art.40726","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"4877_CR12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.reuma.2017.08.007","volume":"14","author":"JC Torre Alonso","year":"2018","unstructured":"Torre Alonso JC, Del Campo D, Fontecha P, Almodovar R, Canete JD, Montilla Morales C, Moreno M, Plasencia-Rodriguez C, Ramirez Garcia J, Queiro R (2018) Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis. Reumatol Clin 14(5):254\u2013268. https:\/\/doi.org\/10.1016\/j.reuma.2017.08.007","journal-title":"Reumatol Clin"},{"issue":"9","key":"4877_CR13","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/ard.2008.094946","volume":"68","author":"CT Ritchlin","year":"2009","unstructured":"Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, de Vlam K, Fiorentino D, Fitzgerald O, Gottlieb AB, McHugh NJ, Nash P, Qureshi AA, Soriano ER, Taylor WJ, Group for R, Assessment of P, Psoriatic A (2009) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 68(9):1387\u20131394. https:\/\/doi.org\/10.1136\/ard.2008.094946","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4877_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1\u201312","journal-title":"Control Clin Trials"},{"key":"4877_CR15","unstructured":"(CEBM) OUCfE-BM (2011) CEBM Levels of Evidence 2011. https:\/\/www.cebm.net\/. Accessed 29 Sept 2020"},{"issue":"1","key":"4877_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","volume":"47","author":"JF Merola","year":"2017","unstructured":"Merola JF, Lockshin B, Mody EA (2017) Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum 47(1):29\u201337. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.02.001","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"4877_CR17","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3899\/jrheum.150614","volume":"43","author":"LC Coates","year":"2016","unstructured":"Coates LC, Helliwell PS (2016) Methotrexate efficacy in the tight control in psoriatic arthritis study. J Rheumatol 43(2):356\u2013361. https:\/\/doi.org\/10.3899\/jrheum.150614","journal-title":"J Rheumatol"},{"issue":"6","key":"4877_CR18","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/ard.2004.024463","volume":"64","author":"AD Fraser","year":"2005","unstructured":"Fraser AD, van Kuijk AW, Westhovens R, Karim Z, Wakefield R, Gerards AH, Landew\u00e9 R, Steinfeld SD, Emery P, Dijkmans BA et al (2005) A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 64(6):859\u2013864. https:\/\/doi.org\/10.1136\/ard.2004.024463","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"4877_CR19","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","volume":"51","author":"GH Kingsley","year":"2012","unstructured":"Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ, Mulherin DM, Kitas GD, Chakravarty K, Tom BD et al (2012) A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 51(8):1368\u20131377. https:\/\/doi.org\/10.1093\/rheumatology\/kes001","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"4877_CR20","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s10067-007-0787-7","volume":"27","author":"R Scarpa","year":"2008","unstructured":"Scarpa R, Peluso R, Atteno M, Manguso F, Span\u00f2 A, Iervolino S, Di Minno MN, Costa L, Del Puente A (2008) The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol 27(7):823\u2013826. https:\/\/doi.org\/10.1007\/s10067-007-0787-7","journal-title":"Clin Rheumatol"},{"issue":"4","key":"4877_CR21","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/art.1780270403","volume":"27","author":"RF Willkens","year":"1984","unstructured":"Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, Cathcart ES, Samuelson CO Jr, Solsky MA, Kaplan SB (1984) Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 27(4):376\u2013381. https:\/\/doi.org\/10.1002\/art.1780270403","journal-title":"Arthritis Rheum"},{"issue":"12","key":"4877_CR22","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1002\/art.1780391210","volume":"39","author":"DO Clegg","year":"1996","unstructured":"Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, Budiman-Mak E, Blackburn WD, Vasey FB, Mahowald ML et al (1996) Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39(12):2013\u20132020. https:\/\/doi.org\/10.1002\/art.1780391210","journal-title":"Arthritis Rheum"},{"issue":"7","key":"4877_CR23","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/rheumatology\/35.7.664","volume":"35","author":"B Combe","year":"1996","unstructured":"Combe B, Goupille P, Kuntz JL, Tebib J, Liot\u00e9 F, Bregeon C (1996) Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br J Rheumatol 35(7):664\u2013668. https:\/\/doi.org\/10.1093\/rheumatology\/35.7.664","journal-title":"Br J Rheumatol"},{"issue":"5","key":"4877_CR24","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/art.1780380507","volume":"38","author":"M Dougados","year":"1995","unstructured":"Dougados M, vam der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, Zeidler H, Kvien TK, Olivieri I, Dijkmans B (1995) Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 38(5):618\u2013627. https:\/\/doi.org\/10.1002\/art.1780380507","journal-title":"Arthritis Rheum"},{"issue":"10","key":"4877_CR25","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/rheumatology\/32.10.923","volume":"32","author":"SM Fraser","year":"1993","unstructured":"Fraser SM, Hopkins R, Hunter JA, Neumann V, Capell HA, Bird HA (1993) Sulphasalazine in the management of psoriatic arthritis. Br J Rheumatol 32(10):923\u2013925. https:\/\/doi.org\/10.1093\/rheumatology\/32.10.923","journal-title":"Br J Rheumatol"},{"issue":"6","key":"4877_CR26","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1002\/art.20253","volume":"50","author":"JP Kaltwasser","year":"2004","unstructured":"Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, Wollenhaupt J, Falk FG, Mease P (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50(6):1939\u20131950. https:\/\/doi.org\/10.1002\/art.20253","journal-title":"Arthritis Rheum"},{"issue":"3","key":"4877_CR27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000091251","volume":"212","author":"P Nash","year":"2006","unstructured":"Nash P, Tha\u00e7i D, Behrens F, Falk F, Kaltwasser JP (2006) Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology (Basel, switzerland) 212(3):238\u2013249. https:\/\/doi.org\/10.1159\/000091251","journal-title":"Dermatology (Basel, switzerland)"},{"issue":"2","key":"4877_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/bf02249014","volume":"13","author":"W Br\u00fcckle","year":"1994","unstructured":"Br\u00fcckle W, Dexel T, Grasedyck K, Schattenkirchner M (1994) Treatment of psoriatic arthritis with auranofin and gold sodium thiomalate. Clin Rheumatol 13(2):209\u2013216. https:\/\/doi.org\/10.1007\/bf02249014","journal-title":"Clin Rheumatol"},{"issue":"4","key":"4877_CR29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/rheumatology\/29.4.280","volume":"29","author":"J Palit","year":"1990","unstructured":"Palit J, Hill J, Capell HA, Carey J, Daunt SO, Cawley MI, Bird HA, Nuki G (1990) A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol 29(4):280\u2013283. https:\/\/doi.org\/10.1093\/rheumatology\/29.4.280","journal-title":"Br J Rheumatol"},{"issue":"4","key":"4877_CR30","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1136\/ard.2010.130864","volume":"70","author":"F Atzeni","year":"2011","unstructured":"Atzeni F, Boccassini L, Antivalle M, Salaffi F, Sarzi-Puttini P (2011) Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. Ann Rheum Dis 70(4):712\u2013714. https:\/\/doi.org\/10.1136\/ard.2010.130864","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4877_CR31","first-page":"589","volume":"13","author":"A Spadaro","year":"1995","unstructured":"Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A (1995) Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 13(5):589\u2013593","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"4877_CR32","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/bf01450970","volume":"17","author":"A Spadaro","year":"1998","unstructured":"Spadaro A, Taccari E, Sensi F, Riccieri V, Sili Scavalli A, Zoppini A (1998) Soluble interleukin-2 receptor and interleukin-6 levels: evaluation during cyclosporin A and methotrexate treatment in psoriatic arthritis. Clin Rheumatol 17(1):83\u201385. https:\/\/doi.org\/10.1007\/bf01450970","journal-title":"Clin Rheumatol"},{"issue":"8","key":"4877_CR33","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/ard.2004.032268","volume":"64","author":"C Antoni","year":"2005","unstructured":"Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A, Investigators IT (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64(8):1150\u20131157. https:\/\/doi.org\/10.1136\/ard.2004.032268","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4877_CR34","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"CE Antoni","year":"2005","unstructured":"Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52(4):1227\u20131236. https:\/\/doi.org\/10.1002\/art.20967","journal-title":"Arthritis Rheum"},{"issue":"5","key":"4877_CR35","first-page":"869","volume":"35","author":"CE Antoni","year":"2008","unstructured":"Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B, Kirkham B, Tutuncu Z, Burmester GR, Schneider U et al (2008) Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 35(5):869\u2013876","journal-title":"J Rheumatol"},{"issue":"4","key":"4877_CR36","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/ard.2011.152223","volume":"71","author":"A Baranauskaite","year":"2012","unstructured":"Baranauskaite A, Raffayov\u00e1 H, Kungurov NV, Kubanova A, Venalis A, Helmle L, Srinivasan S, Nasonov E, Vastesaeger N (2012) Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 71(4):541\u2013548. https:\/\/doi.org\/10.1136\/ard.2011.152223","journal-title":"Ann Rheum Dis"},{"issue":"10086","key":"4877_CR37","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK J\u00f8rgensen","year":"2017","unstructured":"J\u00f8rgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, M\u00f8rk C, Jahnsen J, Kvien TK (2017) Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet (London, England) 389(10086):2304\u20132316. https:\/\/doi.org\/10.1016\/S0140-6736(17)30068-5","journal-title":"Lancet (London, England)"},{"issue":"4","key":"4877_CR38","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1136\/ard.2006.058339","volume":"66","author":"A Kavanaugh","year":"2007","unstructured":"Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP et al (2007) Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 66(4):498\u2013505. https:\/\/doi.org\/10.1136\/ard.2006.058339","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4877_CR39","first-page":"1040","volume":"34","author":"MC Genovese","year":"2007","unstructured":"Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, Medich J, Sasso EH (2007) Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 34(5):1040\u20131050","journal-title":"J Rheumatol"},{"issue":"10","key":"4877_CR40","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52(10):3279\u20133289. https:\/\/doi.org\/10.1002\/art.21306","journal-title":"Arthritis Rheum"},{"issue":"5","key":"4877_CR41","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3899\/jrheum.120970","volume":"40","author":"PJ Mease","year":"2013","unstructured":"Mease PJ, Heckaman M, Kary S, Kupper H (2013) Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT. J Rheumatol 40(5):647\u2013652. https:\/\/doi.org\/10.3899\/jrheum.120970","journal-title":"J Rheumatol"},{"issue":"11","key":"4877_CR42","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/j.1468-3083.2011.04308.x","volume":"26","author":"R Gniadecki","year":"2012","unstructured":"Gniadecki R, Robertson D, Molta CT, Freundlich B, Pedersen R, Li W, Boggs R, Zbrozek AS (2012) Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens. J Eur Acad Dermatol Venereol 26(11):1436\u20131443. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04308.x","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"4877_CR43","first-page":"11","volume":"33","author":"B Kirkham","year":"2015","unstructured":"Kirkham B, de Vlam K, Li W, Boggs R, Mallbris L, Nab HW, Tarallo M (2015) Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial. Clin Exp Rheumatol 33(1):11\u201319","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"4877_CR44","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.40851","volume":"71","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L, Kricorian G, Chung JB (2019) Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol (Hoboken, NJ) 71(7):1112\u20131124. https:\/\/doi.org\/10.1002\/art.40851","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"9227","key":"4877_CR45","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"PJ Mease","year":"2000","unstructured":"Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (London, England) 356(9227):385\u2013390. https:\/\/doi.org\/10.1016\/S0140-6736(00)02530-7","journal-title":"Lancet (London, England)"},{"issue":"4","key":"4877_CR46","first-page":"712","volume":"33","author":"PJ Mease","year":"2006","unstructured":"Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Dunn M et al (2006) Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 33(4):712\u2013721","journal-title":"J Rheumatol"},{"issue":"7","key":"4877_CR47","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"PJ Mease","year":"2004","unstructured":"Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50(7):2264\u20132272. https:\/\/doi.org\/10.1002\/art.20335","journal-title":"Arthritis Rheum"},{"key":"4877_CR48","doi-asserted-by":"publisher","first-page":"c147","DOI":"10.1136\/bmj.c147","volume":"340","author":"W Sterry","year":"2010","unstructured":"Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, Estojak J, Molta CT, Freundlich B (2010) Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ (Clinical Res Ed) 340:c147. https:\/\/doi.org\/10.1136\/bmj.c147","journal-title":"BMJ (Clinical Res Ed)"},{"issue":"1","key":"4877_CR49","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","volume":"73","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T et al (2014) Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 73(1):48\u201355. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203696","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4877_CR50","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1007\/s10067-018-4227-7","volume":"37","author":"JA Walsh","year":"2018","unstructured":"Walsh JA, Gottlieb AB, Hoepken B, Nurminen T, Mease PJ (2018) Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial. Clin Rheumatol 37(12):3285\u20133296. https:\/\/doi.org\/10.1007\/s10067-018-4227-7","journal-title":"Clin Rheumatol"},{"issue":"8","key":"4877_CR51","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1136\/annrheumdis-2016-210775","volume":"76","author":"P Carron","year":"2017","unstructured":"Carron P, Varkas G, Cypers H, Van Praet L, Elewaut D, Van den Bosch F (2017) Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study. Ann Rheum Dis 76(8):1389\u20131395. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210775","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"4877_CR52","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/art.40226","volume":"69","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC (2017) Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results Through Week Twenty-Four of the GO-VIBRANT Study. Arthritis Rheumatol (Hoboken, NJ) 69(11):2151\u20132161. https:\/\/doi.org\/10.1002\/art.40226","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"4","key":"4877_CR53","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/art.24403","volume":"60","author":"A Kavanaugh","year":"2009","unstructured":"Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M et al (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60(4):976\u2013986. https:\/\/doi.org\/10.1002\/art.24403","journal-title":"Arthritis Rheum"},{"issue":"10","key":"4877_CR54","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/acr.22044","volume":"65","author":"A Kavanaugh","year":"2013","unstructured":"Kavanaugh A, McInnes IB, Krueger GG, Gladman D, Beutler A, Gathany T, Mack M, Tandon N, Han C, Mease P (2013) Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care Res 65(10):1666\u20131673. https:\/\/doi.org\/10.1002\/acr.22044","journal-title":"Arthritis Care Res"},{"issue":"9","key":"4877_CR55","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1136\/annrheumdis-2013-204902","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, McInnes IB, Mease P, Krueger GG, Gladman D, van der Heijde D, Zhou Y, Lu J, Leu JH, Goldstein N et al (2014) Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis 73(9):1689\u20131694. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204902","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4877_CR56","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/acr.22576","volume":"68","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, van der Heijde D, Beutler A, Gladman D, Mease P, Krueger GG, McInnes IB, Helliwell P, Coates LC, Xu S (2016) Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study. Arthritis Care Res 68(2):267\u2013274. https:\/\/doi.org\/10.1002\/acr.22576","journal-title":"Arthritis Care Res"},{"issue":"8","key":"4877_CR57","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/art.34436","volume":"64","author":"A Kavanaugh","year":"2012","unstructured":"Kavanaugh A, van der Heijde D, McInnes IB, Mease P, Krueger GG, Gladman DD, G\u00f3mez-Reino J, Papp K, Baratelle A, Xu W et al (2012) Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 64(8):2504\u20132517. https:\/\/doi.org\/10.1002\/art.34436","journal-title":"Arthritis Rheum"},{"issue":"5","key":"4877_CR58","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1136\/annrheumdis-2018-214746","volume":"78","author":"LJJ van Mens","year":"2019","unstructured":"van Mens LJJ, de Jong HM, Fluri I, Nurmohamed MT, van de Sande MGH, Kok M, van Kuijk AWR, Baeten D (2019) Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate. Ann Rheum Dis 78(5):610\u2013616. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214746","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"4877_CR59","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1093\/rheumatology\/key173","volume":"57","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Weinblatt ME, Mease PJ, Aelion JA, Peloso PM, Chen K, Li Y, Liu J, Othman AA, Khatri A et al (2018) Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis. Rheumatology (Oxford) 57(11):1972\u20131981. https:\/\/doi.org\/10.1093\/rheumatology\/key173","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"4877_CR60","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, Banerjee S, Gladman DD (2017) Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis 76(9):1550\u20131558. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210724","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4877_CR61","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s13075-018-1769-7","volume":"20","author":"V Strand","year":"2018","unstructured":"Strand V, Alemao E, Lehman T, Johnsen A, Banerjee S, Ahmad HA, Mease PJ (2018) Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial. Arthritis Res Ther 20(1):269. https:\/\/doi.org\/10.1186\/s13075-018-1769-7","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"4877_CR62","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13075-018-1773-y","volume":"20","author":"LC Coates","year":"2018","unstructured":"Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, Gossec L, Strand V, Rasouliyan L, Pricop L et al (2018) Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study. Arthritis Res Ther 20(1):272. https:\/\/doi.org\/10.1186\/s13075-018-1773-y","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"4877_CR63","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/acr.23537","volume":"70","author":"LC Coates","year":"2018","unstructured":"Coates LC, Mease PJ, Gossec L, Kirkham B, Sherif B, Gaillez C, Mpofu S, Jugl SM, Karyekar C, Gandhi KK (2018) Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2-year results from a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III study. Arthritis Care Res 70(10):1529\u20131535. https:\/\/doi.org\/10.1002\/acr.23537","journal-title":"Arthritis Care Res"},{"issue":"9","key":"4877_CR64","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3899\/jrheum.160275","volume":"43","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, McInnes IB, Mease PJ, Hall S, Chinoy H, Kivitz AJ, Wang Z, Mpofu S (2016) Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study. J Rheumatol 43(9):1713\u20131717. https:\/\/doi.org\/10.3899\/jrheum.160275","journal-title":"J Rheumatol"},{"issue":"3","key":"4877_CR65","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/acr.23111","volume":"69","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Mease PJ, Reimold AM, Tahir H, Rech J, Hall S, Geusens P, Wang Z, Pricop L, Mpofu S (2017) Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase III, randomized, double-blind placebo-controlled study. Arthritis Care Res 69(3):347\u2013355. https:\/\/doi.org\/10.1002\/acr.23111","journal-title":"Arthritis Care Res"},{"issue":"9999","key":"4877_CR66","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landew\u00e9 R, Conaghan PG, Gottlieb AB et al (2015) Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England) 386(9999):1137\u20131146. https:\/\/doi.org\/10.1016\/S0140-6736(15)61134-5","journal-title":"Lancet (London, England)"},{"issue":"11","key":"4877_CR67","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","volume":"56","author":"IB McInnes","year":"2017","unstructured":"McInnes IB, Mease PJ, Ritchlin CT, Rahman P, Gottlieb AB, Kirkham B, Kajekar R, Delicha EM, Pricop L, Mpofu S (2017) Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford) 56(11):1993\u20132003. https:\/\/doi.org\/10.1093\/rheumatology\/kex301","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"4877_CR68","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","volume":"73","author":"IB McInnes","year":"2014","unstructured":"McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, Dahmen G, Wollenhaupt J, Schulze-Koops H, Kogan J et al (2014) Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 73(2):349\u2013356. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202646","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4877_CR69","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","volume":"77","author":"P Mease","year":"2018","unstructured":"Mease P, van der Heijde D, Landew\u00e9 R, Mpofu S, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Meiser K et al (2018) Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis 77(6):890\u2013897. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212687","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"4877_CR70","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landew\u00e9 R, Nash P, Pricop L, Yuan J et al (2015) Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 373(14):1329\u20131339. https:\/\/doi.org\/10.1056\/NEJMoa1412679","journal-title":"N Engl J Med"},{"issue":"1","key":"4877_CR71","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","volume":"20","author":"P Nash","year":"2018","unstructured":"Nash P, Mease PJ, McInnes IB, Rahman P, Ritchlin CT, Blanco R, Dokoupilova E, Andersson M, Kajekar R, Mpofu S et al (2018) Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther 20(1):47. https:\/\/doi.org\/10.1186\/s13075-018-1551-x","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"4877_CR72","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, Tahir H, Gooderham M, Krishnan E, Liu-Seifert H, Emery P, Pillai SG, Helliwell PS, group SHHs, (2020) A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis 79(1):123\u2013131. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215386","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4877_CR73","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD (2017) Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 76(1):79\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209709","journal-title":"Ann Rheum Dis"},{"key":"4877_CR74","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000692","author":"P Nash","year":"2018","unstructured":"Nash P, Behrens F, Orbai AM, Rathmann SS, Adams DH, Benichou O, Deodhar A (2018) Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2018-000692","journal-title":"RMD Open"},{"issue":"10086","key":"4877_CR75","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","volume":"389","author":"P Nash","year":"2017","unstructured":"Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL et al (2017) Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet (london, england) 389(10086):2317\u20132327. https:\/\/doi.org\/10.1016\/S0140-6736(17)31429-0","journal-title":"Lancet (london, england)"},{"issue":"3","key":"4877_CR76","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3899\/jrheum.170429","volume":"45","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Gladman DD, Kishimoto M, Okada M, Rathmann SS, Moriarty SR, Shuler CL, Carlier H, Benichou O, Mease PJ (2018) Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1). J Rheumatol 45(3):367\u2013377. https:\/\/doi.org\/10.3899\/jrheum.170429","journal-title":"J Rheumatol"},{"issue":"11","key":"4877_CR77","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/rheumatology\/key182","volume":"57","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Combe B, Kremer JM, Tsai TF, Behrens F, Adams DH, Lee C, Kerr L, Nash P (2018) Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2. Rheumatology (Oxford) 57(11):2001\u20132011. https:\/\/doi.org\/10.1093\/rheumatology\/key182","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"4877_CR78","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","volume":"48","author":"EG Araujo","year":"2019","unstructured":"Araujo EG, Englbrecht M, Hoepken S, Finzel S, Kampylafka E, Kleyer A, Bayat S, Schoenau V, Hueber A, Rech J et al (2019) Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum 48(4):632\u2013637. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.05.011","journal-title":"Semin Arthritis Rheum"},{"issue":"9664","key":"4877_CR79","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","volume":"373","author":"A Gottlieb","year":"2009","unstructured":"Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A (2009) Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet (London, England) 373(9664):633\u2013640. https:\/\/doi.org\/10.1016\/S0140-6736(09)60140-9","journal-title":"Lancet (London, England)"},{"issue":"12","key":"4877_CR80","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/acr.22645","volume":"67","author":"A Kavanaugh","year":"2015","unstructured":"Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, Li S, Wang Y, Mendelsohn AM, Song M, Zhu Y, Rahman P et al (2015) Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res 67(12):1739\u20131749. https:\/\/doi.org\/10.1002\/acr.22645","journal-title":"Arthritis Care Res"},{"issue":"9894","key":"4877_CR81","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM et al (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet (London, England) 382(9894):780\u2013789. https:\/\/doi.org\/10.1016\/S0140-6736(13)60594-2","journal-title":"Lancet (London, England)"},{"issue":"6","key":"4877_CR82","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM et al (2014) Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73(6):990\u2013999. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204655","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"4877_CR83","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T et al (2017) Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 377(16):1525\u20131536. https:\/\/doi.org\/10.1056\/NEJMoa1615977","journal-title":"N Engl J Med"},{"issue":"16","key":"4877_CR84","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cie\u015blak D, Graham D, Wang C, Menon S et al (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 377(16):1537\u20131550. https:\/\/doi.org\/10.1056\/NEJMoa1615975","journal-title":"N Engl J Med"},{"issue":"9","key":"4877_CR85","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.3899\/jrheum.151376","volume":"43","author":"M Cutolo","year":"2016","unstructured":"Cutolo M, Myerson GE, Fleischmann RM, Liot\u00e9 F, D\u00edaz-Gonz\u00e1lez F, Van den Bosch F, Marzo-Ortega H, Feist E, Shah K, Hu C et al (2016) A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 Trial. J Rheumatol 43(9):1724\u20131734. https:\/\/doi.org\/10.3899\/jrheum.151376","journal-title":"J Rheumatol"},{"issue":"6","key":"4877_CR86","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","volume":"75","author":"CJ Edwards","year":"2016","unstructured":"Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, Stevens RM, Vessey A, Zhan X, Bird P (2016) Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis 75(6):1065\u20131073. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207963","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4877_CR87","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3899\/jrheum.140647","volume":"42","author":"A Kavanaugh","year":"2015","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Hochfeld M, Teng LL, Schett G, Lespessailles E et al (2015) Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol 42(3):479\u2013488. https:\/\/doi.org\/10.3899\/jrheum.140647","journal-title":"J Rheumatol"},{"issue":"6","key":"4877_CR88","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Lespessailles E, Hall S, Hochfeld M, Hu C et al (2014) Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 73(6):1020\u20131026. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205056","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4877_CR89","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1136\/annrheumdis-2017-211568","volume":"77","author":"P Nash","year":"2018","unstructured":"Nash P, Ohson K, Walsh J, Delev N, Nguyen D, Teng L, G\u00f3mez-Reino JJ, Aelion JA (2018) Early and sustained efficacy with apremilast monotherapy in biological-na\u00efve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis 77(5):690\u2013698. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211568","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"4877_CR90","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1002\/art.34627","volume":"64","author":"G Schett","year":"2012","unstructured":"Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, Hu C, Stevens R, de Vlam KL (2012) Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 64(10):3156\u20133167. https:\/\/doi.org\/10.1002\/art.34627","journal-title":"Arthritis Rheum"},{"issue":"1080\/03009742","key":"4877_CR91","first-page":"1803398","volume":"10","author":"FR Kasiem","year":"2020","unstructured":"Kasiem FR, Luime JJ, Vis M, Kok MR, Wervers K, Gerards AH, Appels C, van der Graaff WL, Starmans-Kool M, Goekoop-Ruiterman Y, van Groenendael J, Korswagen LA, Veris-van Dieren JJ, Hazes J (2020) Tchetverikov I (2020) Lessons learned from clinical phenotypes in early psoriatic arthritis: the real-world Dutch south west Early Psoriatic ARthritis study. Scand J Rheumatol 10(1080\/03009742):1803398","journal-title":"Scand J Rheumatol"},{"issue":"8","key":"4877_CR92","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1007\/s10067-020-05003-9","volume":"39","author":"F Abji","year":"2020","unstructured":"Abji F, Ye JY, Cook RJ, Oikonomopoulou K, Chandran V (2020) The association between synovial fluid serine proteinase activity and response to intra-articular corticosteroid injection in psoriatic arthritis. Clin Rheumatol 39(8):2355\u20132361. https:\/\/doi.org\/10.1007\/s10067-020-05003-9","journal-title":"Clin Rheumatol"},{"issue":"2","key":"4877_CR93","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/0394632015593220","volume":"29","author":"F Carubbi","year":"2016","unstructured":"Carubbi F, Zugaro L, Cipriani P, Conchiglia A, Gregori L, Danniballe C, Letizia Pistoia M, Liakouli V, Ruscitti P, Ciccia F, Triolo G, Masciocchi C, Giacomelli R (2016) Safety and efficacy of intra-articular anti-tumor necrosis factor \u03b1 agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare. Int J Immunopathol Pharmacol 29(2):252\u2013266. https:\/\/doi.org\/10.1177\/0394632015593220","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"7","key":"4877_CR94","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/rheumatology\/keq102","volume":"49","author":"L Eder","year":"2010","unstructured":"Eder L, Chandran V, Ueng J, Bhella S, Lee KA, Rahman P, Pope A, Cook RJ, Gladman DD (2010) Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford) 49(7):1367\u20131373. https:\/\/doi.org\/10.1093\/rheumatology\/keq102","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"4877_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/rap\/rkx019","volume":"2","author":"SB Ureyen","year":"2018","unstructured":"Ureyen SB, Ivory C, Kalyoncu U, Karsh J, Aydin SZ (2018) What does evidence-based medicine tell us about treatments for different subtypes of psoriatic arthritis? A systematic literature review on randomized controlled trials. Rheumatol Adv Practice 2(1):1\u201315. https:\/\/doi.org\/10.1093\/rap\/rkx019","journal-title":"Rheumatol Adv Practice"},{"issue":"2","key":"4877_CR96","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40744-018-0131-5","volume":"5","author":"P Nash","year":"2018","unstructured":"Nash P, Coates LC, Fleischmann R, Papp KA, Gomez-Reino JJ, Kanik KS, Wang C, Wu J, Menon S, Hendrikx T, Ports WC (2018) Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies. Rheumatol Ther 5(2):567\u2013582. https:\/\/doi.org\/10.1007\/s40744-018-0131-5","journal-title":"Rheumatol Ther"},{"issue":"11","key":"4877_CR97","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1136\/annrheumdis-2015-209068","volume":"75","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, You Y, Li S, Song M, Randazzo B, Rahman P, McInnes IB (2016) Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2). Ann Rheum Dis 75(11):1984\u20131988. https:\/\/doi.org\/10.1136\/annrheumdis-2015-209068","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4877_CR98","first-page":"80","volume":"29","author":"E Lubrano","year":"2011","unstructured":"Lubrano E, Spadaro A, Marchesoni A, Olivieri I, Scarpa R, D\u2019Angelo S, Salvarani C, Mathieu A, Cauli A, Ferrara N, Helliwell P (2011) The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept. Clin Exp Rheumatol 29(1):80\u201384","journal-title":"Clin Exp Rheumatol"},{"key":"4877_CR99","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218808","author":"X Baraliakos","year":"2020","unstructured":"Baraliakos X, Gossec L, Pournara E, Jeka S, Mera-Varela A, D\u2019Angelo S, Schulz B, Rissler M, Nagar K, Perella C, Coates LC (2020) Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218808","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4877_CR100","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/rheumatology\/kez457","volume":"59","author":"J Feld","year":"2020","unstructured":"Feld J, Ye JY, Chandran V, Inman RD, Haroon N, Cook R, Gladman DD (2020) Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis? Rheumatology (Oxford) 59(6):1340\u20131346. https:\/\/doi.org\/10.1093\/rheumatology\/kez457","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"4877_CR101","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13075-018-1565-4","volume":"20","author":"M Haroon","year":"2018","unstructured":"Haroon M, Ahmad M, Baig MN, Mason O, Rice J, FitzGerald O (2018) Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study. Arthritis Res Ther 20(1):73. https:\/\/doi.org\/10.1186\/s13075-018-1565-4","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"4877_CR102","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1136\/ard.2011.150995","volume":"71","author":"Z Ash","year":"2012","unstructured":"Ash Z, Gaujoux-Viala C, Gossec L, Hensor EMA, FitzGerald O, Winthrop K, van der Heijde D, Emery P, Smolen JS, Marzo-Ortega H (2012) A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 71(3):319\u2013326. https:\/\/doi.org\/10.1136\/ard.2011.150995","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4877_CR103","first-page":"508","volume":"38","author":"N Simons","year":"2020","unstructured":"Simons N, Degboe Y, Barnetche T, Cantagrel A, Ruyssen-Witrand A, Constantin A (2020) Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes. Clin Exp Rheumatol 38(3):508\u2013515","journal-title":"Clin Exp Rheumatol"},{"key":"4877_CR104","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01585-7","author":"J Gratacos Masmitja","year":"2020","unstructured":"Gratacos Masmitja J, Gonzalez Fernandez CM, Gomez Castro S, Rebollo Laserna FJ (2020) Efficacy of tofacitinib in the treatment of psoriatic arthritis: a systematic review. Adv Ther. https:\/\/doi.org\/10.1007\/s12325-020-01585-7","journal-title":"Adv Ther"},{"issue":"6","key":"4877_CR105","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.3899\/jrheum.140174","volume":"41","author":"CT Ritchlin","year":"2014","unstructured":"Ritchlin CT (2014) Psoriatic enthesitis: an update from the GRAPPA 2013 Annual Meeting. J Rheumatol 41(6):1220\u20131223. https:\/\/doi.org\/10.3899\/jrheum.140174","journal-title":"J Rheumatol"},{"issue":"1","key":"4877_CR106","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/rheumatology\/kex079","volume":"57","author":"A Marchesoni","year":"2018","unstructured":"Marchesoni A, De Marco G, Merashli M, McKenna F, Tinazzi I, Marzo-Ortega H, McGonagle DG (2018) The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia. Rheumatology (Oxford) 57(1):32\u201340. https:\/\/doi.org\/10.1093\/rheumatology\/kex079","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"4877_CR107","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.3899\/jrheum.150165","volume":"42","author":"M Geijer","year":"2015","unstructured":"Geijer M, Lindqvist U, Husmark T, Alenius GM, Larsson PT, Teleman A, Theander E (2015) The Swedish early psoriatic arthritis registry 5-year followup: substantial radiographic progression mainly in men with high disease activity and development of dactylitis. J Rheumatol 42(11):2110\u20132117. https:\/\/doi.org\/10.3899\/jrheum.150165","journal-title":"J Rheumatol"},{"issue":"11","key":"4877_CR108","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1007\/s10067-020-05142-z","volume":"39","author":"N Girolimetto","year":"2020","unstructured":"Girolimetto N, Macchioni P, Citriniti G, Tinazzi I, Bascherini V, Martinis F, Marchetta A, Possemato N, Tasso M, Peluso R, Punzi L, Salvarani C, Scarpa R, McGonagle D, Costa L, Caso F (2020) Effectiveness of steroid injection for hand psoriatic dactylitis: results from a multicentre prospective observational study. Clin Rheumatol 39(11):3383\u20133392. https:\/\/doi.org\/10.1007\/s10067-020-05142-z","journal-title":"Clin Rheumatol"},{"issue":"4","key":"4877_CR109","doi-asserted-by":"publisher","first-page":"500","DOI":"10.2174\/138161282004140213123505","volume":"20","author":"AW Armstrong","year":"2014","unstructured":"Armstrong AW, Brezinski EA, Follansbee MR, Armstrong EJ (2014) Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des 20(4):500\u2013512. https:\/\/doi.org\/10.2174\/138161282004140213123505","journal-title":"Curr Pharm Des"},{"key":"4877_CR110","doi-asserted-by":"publisher","first-page":"CD011535","DOI":"10.1002\/14651858.CD011535.pub3","volume":"1","author":"E Sbidian","year":"2020","unstructured":"Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L (2020) Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 1:CD011535. https:\/\/doi.org\/10.1002\/14651858.CD011535.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"4877_CR111","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04775-2","author":"S Gupta","year":"2021","unstructured":"Gupta S, Syrimi Z, Hughes DM, Zhao SS (2021) Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol Int. https:\/\/doi.org\/10.1007\/s00296-020-04775-2","journal-title":"Rheumatol Int"},{"issue":"6","key":"4877_CR112","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/annrheumdis-2012-202812","volume":"73","author":"MN Di Minno","year":"2014","unstructured":"Di Minno MN, Peluso R, Iervolino S, Russolillo A, Lupoli R, Scarpa R (2014) Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor \u03b1 blockers. Ann Rheum Dis 73(6):1157\u20131162. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202812","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4877_CR113","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.reuma.2015.12.005","volume":"12","author":"E Gal\u00edndez","year":"2016","unstructured":"Gal\u00edndez E, Carmona L (2016) Is obesity in psoriatic arthritis associated with a poorer therapeutic response and more adverse effects of treatment with an anchor drug? Reumatologia Clinica 12(6):307\u2013312. https:\/\/doi.org\/10.1016\/j.reuma.2015.12.005","journal-title":"Reumatologia Clinica"},{"issue":"1","key":"4877_CR114","doi-asserted-by":"publisher","first-page":"e000934","DOI":"10.1136\/rmdopen-2019-000934","volume":"5","author":"IB McInnes","year":"2019","unstructured":"McInnes IB, Ferraccioli G, D\u2019Agostino MA, Le Bars M, Banerjee S, Ahmad HA, Elbez Y, Mease PJ (2019) Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial. RMD Open 5(1):e000934. https:\/\/doi.org\/10.1136\/rmdopen-2019-000934","journal-title":"RMD Open"},{"issue":"3","key":"4877_CR115","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74(3):480\u2013489. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206624","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4877_CR116","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1093\/rheumatology\/keaa683","volume":"60","author":"R Persson","year":"2021","unstructured":"Persson R, Hagberg KW, Qian Y, Vasilakis-Scaramozza C, Jick S (2021) The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids. Rheumatology (Oxford) 60(4):1926\u20131931. https:\/\/doi.org\/10.1093\/rheumatology\/keaa683","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"4877_CR117","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1136\/annrheumdis-2014-205389","volume":"74","author":"P Hojgaard","year":"2015","unstructured":"Hojgaard P, Glintborg B, Hetland ML, Hansen TH, Lage-Hansen PR, Petersen MH, Holland-Fischer M, Nilsson C, Loft AG, Andersen BN, Adelsten T, Jensen J, Omerovic E, Christensen R, Tarp U, Ostgard R, Dreyer L (2015) Association between tobacco smoking and response to tumour necrosis factor alpha inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. Ann Rheum Dis 74(12):2130\u20132136. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205389","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"4877_CR118","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/acr2.11156","volume":"2","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, Paris M, Delev N, Teng L, Wollenhaupt J (2020) Long-term safety and tolerability of apremilast versus placebo in psoriatic arthritis: a pooled safety analysis of three phase III, randomized, controlled trials. ACR Open Rheumatol 2(8):459\u2013470. https:\/\/doi.org\/10.1002\/acr2.11156","journal-title":"ACR Open Rheumatol"},{"issue":"8","key":"4877_CR119","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1111\/jdv.16231","volume":"34","author":"C Vasilakis-Scaramozza","year":"2020","unstructured":"Vasilakis-Scaramozza C, Persson R, Hagberg KW, Jick S (2020) The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database. J Eur Acad Dermatol Venereol 34(8):1755\u20131763. https:\/\/doi.org\/10.1111\/jdv.16231","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"4877_CR120","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jbspin.2018.01.011","volume":"85","author":"T Reygaerts","year":"2018","unstructured":"Reygaerts T, Mitrovic S, Fautrel B, Gossec L (2018) Effect of biologics on fatigue in psoriatic arthritis: a systematic literature review with meta-analysis. Joint Bone Spine 85(4):405\u2013410. https:\/\/doi.org\/10.1016\/j.jbspin.2018.01.011","journal-title":"Joint Bone Spine"},{"issue":"1","key":"4877_CR121","doi-asserted-by":"publisher","first-page":"e000808","DOI":"10.1136\/rmdopen-2018-000808","volume":"5","author":"V Strand","year":"2019","unstructured":"Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Chen L, Kudlacz E, Wu J, Cappelleri JC, Hendrikx T, Hsu MA (2019) Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. RMD Open 5(1):e000808. https:\/\/doi.org\/10.1136\/rmdopen-2018-000808","journal-title":"RMD Open"},{"issue":"1080\/08820139","key":"4877_CR122","first-page":"1714650","volume":"10","author":"HY Zhou","year":"2020","unstructured":"Zhou HY, Guo B, Lufumpa E, Li XM, Chen LH, Meng X, Li BZ (2020) Comparative of the effectiveness and safety of biological agents, tofacitinib, and fecal microbiota transplantation in ulcerative colitis: systematic review and network meta-analysis. Immunol Invest 10(1080\/08820139):1714650","journal-title":"Immunol Invest"},{"issue":"9","key":"4877_CR123","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3748\/wjg.v25.i9.1142","volume":"25","author":"A Damiao","year":"2019","unstructured":"Damiao A, de Azevedo MFC, Carlos AS, Wada MY, Silva TVM, Feitosa FC (2019) Conventional therapy for moderate to severe inflammatory bowel disease: a systematic literature review. World J Gastroenterol 25(9):1142\u20131157. https:\/\/doi.org\/10.3748\/wjg.v25.i9.1142","journal-title":"World J Gastroenterol"},{"issue":"42","key":"4877_CR124","doi-asserted-by":"publisher","first-page":"e8045","DOI":"10.1097\/MD.0000000000008045","volume":"96","author":"A Gomez-Gomez","year":"2017","unstructured":"Gomez-Gomez A, Loza E, Rosario MP, Espinosa G, Morales J, Herreras JM, Munoz-Fernandez S, Cordero-Coma M (2017) Efficacy and safety of immunomodulatory drugs in patients with anterior uveitis: a systematic literature review. Medicine (Baltimore) 96(42):e8045. https:\/\/doi.org\/10.1097\/MD.0000000000008045","journal-title":"Medicine (Baltimore)"},{"key":"4877_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2017.06.059","author":"G Espinosa","year":"2017","unstructured":"Espinosa G, Munoz-Fernandez S, Ruiz G, de Morales JM, Herreras JM, Cordero-Coma M (2017) Treatment recommendations for non-infectious anterior uveitis. Med Clin (Barc). https:\/\/doi.org\/10.1016\/j.medcli.2017.06.059","journal-title":"Med Clin (Barc)"},{"key":"4877_CR126","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001175","author":"H den Braanker","year":"2020","unstructured":"den Braanker H, Wervers K, Mus AMC, Bangoer PS, Davelaar N, Luime J, Tchetverikov I, Hazes JMW, Vis M, Lubberts E, Kok MR (2020) Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2020-001175","journal-title":"RMD Open"},{"issue":"1","key":"4877_CR127","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s13075-019-1998-4","volume":"21","author":"HMY de Jong","year":"2019","unstructured":"de Jong HMY, van Mens LJJ, Nurmohamed MT, Kok MR, van Kuijk AWR, Baeten DLP, van de Sande MGH (2019) Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial. Arthritis Res Ther 21(1):208. https:\/\/doi.org\/10.1186\/s13075-019-1998-4","journal-title":"Arthritis Res Ther"},{"issue":"10012","key":"4877_CR128","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","volume":"386","author":"LC Coates","year":"2015","unstructured":"Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O\u2019Dwyer JL, Meads DM, Emery P, Conaghan PG, Helliwell PS (2015) Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 386(10012):2489\u20132498. https:\/\/doi.org\/10.1016\/S0140-6736(15)00347-5","journal-title":"Lancet"},{"issue":"4","key":"4877_CR129","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/rheumatology\/kez369","volume":"59","author":"LC Coates","year":"2020","unstructured":"Coates LC, Mahmood F, Freeston J, Emery P, Conaghan PG, Helliwell PS (2020) Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial. Rheumatology (Oxford) 59(4):807\u2013810. https:\/\/doi.org\/10.1093\/rheumatology\/kez369","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"4877_CR130","doi-asserted-by":"publisher","first-page":"22","DOI":"10.26442\/terarkh201890522-29","volume":"90","author":"TV Korotaeva","year":"2018","unstructured":"Korotaeva TV, Loginova EY, Getiya TS, Nasonov EL (2018) Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study. Ter Arkh 90(5):22\u201329. https:\/\/doi.org\/10.26442\/terarkh201890522-29","journal-title":"Ter Arkh"},{"issue":"2","key":"4877_CR131","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202641","volume":"73","author":"R Goulabchand","year":"2014","unstructured":"Goulabchand R, Mouterde G, Barnetche T, Lukas C, Morel J, Combe B (2014) Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis 73(2):414\u2013419. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202641","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"4877_CR132","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3899\/jrheum.180971","volume":"46","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Gladman DD, FitzGerald O, Kavanaugh A, Graham D, Wang C, Fallon L (2019) Radiographic progression according to baseline C-reactive protein levels and other risk factors in psoriatic arthritis treated with tofacitinib or adalimumab. J Rheumatol 46(9):1089\u20131096. https:\/\/doi.org\/10.3899\/jrheum.180971","journal-title":"J Rheumatol"},{"issue":"5","key":"4877_CR133","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/rheumatology\/keu415","volume":"54","author":"F Behrens","year":"2015","unstructured":"Behrens F, Ca\u00f1ete JD, Olivieri I, van Kuijk AW, McHugh N, Combe B (2015) Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. Rheumatology (Oxford) 54(5):915\u2013926. https:\/\/doi.org\/10.1093\/rheumatology\/keu415","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"4877_CR134","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.semarthrit.2016.09.005","volume":"46","author":"K Aaltonen","year":"2017","unstructured":"Aaltonen K, Heinonen A, Joensuu J, Parmanne P, Karjalainen A, Varjolahti-Lehtinen T, Uutela T, Puurtinen-Vilkki M, Arstila L, Blom M, Sokka T, Nordstrom D (2017) Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: a prospective cohort study. Semin Arthritis Rheum 46(6):732\u2013739. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.09.005","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"4877_CR135","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3899\/jrheum.140685","volume":"42","author":"M Zisapel","year":"2015","unstructured":"Zisapel M, Zisman D, Madar-Balakirski N, Arad U, Padova H, Matz H, Maman-Sarvagyl H, Kaufman I, Paran D, Feld J, Litinsky I, Wigler I, Caspi D, Elkayam O (2015) Prevalence of TNF-alpha blocker immunogenicity in psoriatic arthritis. J Rheumatol 42(1):73\u201378. https:\/\/doi.org\/10.3899\/jrheum.140685","journal-title":"J Rheumatol"},{"key":"4877_CR136","unstructured":"European Medicines Agency EMA (2021) Xelyanz. Sumary of product. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xeljanz#product-information-section"},{"issue":"2","key":"4877_CR137","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3899\/jrheum.140067","volume":"43","author":"A Haddad","year":"2016","unstructured":"Haddad A, Li S, Thavaneswaran A, Cook RJ, Chandran V, Gladman DD (2016) The incidence and predictors of infection in psoriasis and psoriatic arthritis: results from longitudinal observational cohorts. J Rheumatol 43(2):362\u2013366. https:\/\/doi.org\/10.3899\/jrheum.140067","journal-title":"J Rheumatol"},{"issue":"1","key":"4877_CR138","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jaad.2019.03.017","volume":"81","author":"E Baumrin","year":"2019","unstructured":"Baumrin E, Van Voorhees A, Garg A, Feldman SR, Merola JF (2019) A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 81(1):102\u2013110. https:\/\/doi.org\/10.1016\/j.jaad.2019.03.017","journal-title":"J Am Acad Dermatol"},{"key":"4877_CR139","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw205","author":"F Marra","year":"2016","unstructured":"Marra F, Lo E, Kalashnikov V, Richardson K (2016) Risk of herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and\/or corticosteroids for autoimmune diseases: a systematic review and meta-analysis. Open Forum Infect Dis. https:\/\/doi.org\/10.1093\/ofid\/ofw205","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"4877_CR140","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","volume":"78","author":"S Schreiber","year":"2019","unstructured":"Schreiber S, Colombel JF, Feagan BG, Reich K, Deodhar AA, McInnes IB, Porter B, Das Gupta A, Pricop L, Fox T (2019) Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis 78(4):473\u2013479. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214273","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4877_CR141","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1093\/rheumatology\/keaa189","volume":"59","author":"MC Genovese","year":"2020","unstructured":"Genovese MC, Mysler E, Tomita T, Papp KA, Salvarani C, Schwartzman S, Gallo G, Patel H, Lisse JR, Kronbergs A, Leage SL, Adams DH, Xu W, Marzo-Ortega H, Lebwohl MG (2020) Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatology (Oxford) 59(12):3834\u20133844. https:\/\/doi.org\/10.1093\/rheumatology\/keaa189","journal-title":"Rheumatology (Oxford)"},{"key":"4877_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.07.013","author":"D Fiorentino","year":"2017","unstructured":"Fiorentino D, Ho V, Lebwohl MG, Leite L, Hopkins L, Galindo C, Goyal K, Langholff W, Fakharzadeh S, Srivastava B, Langley RG (2017) Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2017.07.013","journal-title":"J Am Acad Dermatol"},{"key":"4877_CR143","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20925696","author":"YH Kwan","year":"2020","unstructured":"Kwan YH, Lim KK, Fong W, Goh H, Ng L, Haaland B, Phang JK, Low LL, Yeo JG, Huang F, Leung YY, Thumboo J, Ostbye T (2020) Risk of malignancies in patients with spondyloarthritis treated with biologics compared with those treated with non-biologics: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis. https:\/\/doi.org\/10.1177\/1759720X20925696","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"6","key":"4877_CR144","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.semarthrit.2014.11.005","volume":"44","author":"L Silva-Fernandez","year":"2015","unstructured":"Silva-Fernandez L, Perez-Vicente S, Martin-Martinez MA, Lopez-Gonzalez R, em ARIISG (2015) Variability in the prescription of non-biologic disease-modifying antirheumatic drugs for the treatment of spondyloarthritis in Spain. Semin Arthritis Rheum 44(6):633\u2013640. https:\/\/doi.org\/10.1016\/j.semarthrit.2014.11.005","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"4877_CR145","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s40744-020-00202-x","volume":"7","author":"JD Canete","year":"2020","unstructured":"Canete JD, Tasende JAP, Laserna FJR, Castro SG, Queiro R (2020) The impact of comorbidity on patient-reported outcomes in psoriatic arthritis: a systematic literature review. Rheumatol Ther 7(2):237\u2013257. https:\/\/doi.org\/10.1007\/s40744-020-00202-x","journal-title":"Rheumatol Ther"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04877-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-04877-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04877-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T10:07:12Z","timestamp":1627380432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-04877-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,2]]},"references-count":145,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["4877"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-04877-5","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,2]]},"assertion":[{"value":"9 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All of the authors received honoraria from Pfizer for participation in this project. Francisco Rebollo and Susana G\u00f3mez work for Pfizer. Agust\u00ed Sellas has received honoraria as speaker and for consulting from Pfizer, Lilly Novartis, Janssen, Amgen. Julio Ram\u00edrez has participated at symposiums and\/or advisory boards organised by Pfizer, Abbvie, MSD, UCB, Novartis, BMS, Lilly, Janssen, Amgen and Roche and his department has received research grants from Pfizer, Abbvie, Novartis and Janssen. Rub\u00e9n Queiro has received honoraria as speaker, researcher and consultor from Janssen, Lilly, MSD, Abbvie, Pfizer, UCB, Celgene-Amgen, Novartis. Rosario Garc\u00eda-Vicu\u00f1a reports personal fees from Pfizer, during the conduct of the study; grants, personal fees and non-financial support from Abbvie, grants, personal fees and non-financial support from BMS, personal fees from Biogen, personal fees from Celltrion, grants, personal fees and non-financial support from Lilly, grants, personal fees and non-financial support from Novartis, grants, personal fees and non-financial support from MSD, personal fees and non-financial support from Pfizer, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants from Janssen, outside the submitted work. Estibaliz Loza has received research grants from Janssen, Lilly, MSD, Abbvie, Pfizer, UCB, Celgene-Amgen, Roche, Abbvie, BMS, Novartis. Noem\u00ed Garrido has received personal fees from Pfizer, Abbie, Lilly, Gedeon Richter, Novartis, Sanofi y Janssen. The rest of authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}